Licensing/Marketing Agreements

No Picture
News

EpicentRx Inc. and SciClone Pharmaceuticals Establish Licensing Agreement for RRx-001 in Greater China

July 1, 2020 sandiegobiotech Comments Off on EpicentRx Inc. and SciClone Pharmaceuticals Establish Licensing Agreement for RRx-001 in Greater China

SciClone granted exclusive license to co-develop and commercialize RRx-001 upon approval in the Greater China Region

LA JOLLA, Calif., July 1, 2020 /PRNewswire/ — EpicentRx Inc. (“EpicentRx”), a San Diego-based clinical cancer immunotherapy company … […]

No Picture
News

Qualigen Therapeutics Signs Exclusive License Agreement with the University of Louisville, Plans to Develop AS1411 for the Treatment of COVID-19

June 10, 2020 sandiegobiotech Comments Off on Qualigen Therapeutics Signs Exclusive License Agreement with the University of Louisville, Plans to Develop AS1411 for the Treatment of COVID-19

CARLSBAD, Calif., June 10, 2020 /PRNewswire/ — Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (Qualigen or the Company) announced today the signing of an exclusive license agreement with the University of Louisville (UofL) to facilitate developme… […]

No Picture
News

Qualigen Therapeutics Releases FastPack® SARS-CoV-2 Antibody Diagnostic Test to University of Louisville to Conduct Validation Studies

June 2, 2020 sandiegobiotech Comments Off on Qualigen Therapeutics Releases FastPack® SARS-CoV-2 Antibody Diagnostic Test to University of Louisville to Conduct Validation Studies

CARLSBAD, Calif., June 2, 2020 /PRNewswire/ — Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (Qualigen or the Company) announced today that the Company has released a pre-launch supply of its proposed FastPack® SARS-CoV-2 IgG Immunoassay diagnostic tes… […]

No Picture
News

Vividion Therapeutics Announces Drug Discovery Collaboration with Roche Focused on Novel E3 Ligases

May 18, 2020 sandiegobiotech Comments Off on Vividion Therapeutics Announces Drug Discovery Collaboration with Roche Focused on Novel E3 Ligases

Multi-Target Collaboration Leverages Vividion’s Screening Platform to Discover and Develop Highly Selective Small Molecules for E3 Ligases and Select Oncology and Immunology TargetsVividion Receives $135 Million Upfront Payment With Potential for Multi… […]

No Picture
News

Natera and Illumina Settle Patent Dispute

May 18, 2020 sandiegobiotech Comments Off on Natera and Illumina Settle Patent Dispute

SAN CARLOS, Calif. and SAN DIEGO, May 18, 2020 /PRNewswire/ — Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, and Illumina Inc. (NASDAQ: ILMN), a global leader in next-generation sequencing platforms, today announ… […]

No Picture
News

Ajinomoto Bio-Pharma Services Announces Manufacturing Partnership with CytoDyn for Drug Product Used in COVID-19 Clinical Trials

May 5, 2020 sandiegobiotech Comments Off on Ajinomoto Bio-Pharma Services Announces Manufacturing Partnership with CytoDyn for Drug Product Used in COVID-19 Clinical Trials

SAN DIEGO, May 5, 2020 /PRNewswire/ –?Ajinomoto Bio-Pharma Services (“Aji Bio-Pharma”), a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce it has entered into a manufacturing services agr… […]

No Picture
News

Halozyme Announces Janssen Receives FDA Approval Of DARZALEX FASPRO(TM) Utilizing Halozyme’s ENHANZE® Technology For The Treatment Of Patients With Multiple Myeloma

May 1, 2020 sandiegobiotech Comments Off on Halozyme Announces Janssen Receives FDA Approval Of DARZALEX FASPRO(TM) Utilizing Halozyme’s ENHANZE® Technology For The Treatment Of Patients With Multiple Myeloma

– Janssen’s DARZALEX FASPRO(TM) is a subcutaneous co-formulation of DARZALEX? and Halozyme’s ENHANZE? technology — Innovative, fixed-dose formulation demonstrates consistent efficacy to intravenous DARZALEX? with lower rate of infusion-related reactio… […]

No Picture
News

Forge Enters Into Collaboration With Roche To Develop Novel Antibiotic To Treat Lung Infections

March 25, 2020 sandiegobiotech Comments Off on Forge Enters Into Collaboration With Roche To Develop Novel Antibiotic To Treat Lung Infections

-Forge is eligible to receive $190.5M in total payments-

SAN DIEGO, March 25, 2020 /PRNewswire/ — Forge Therapeutics, Inc. (Forge) announced today that they have entered into a research collaboration and option agreement with Hoffmann-La Roche Ltd. … […]